Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan

Journal of Infection and Chemotherapy

Volumn 6, Issue 2, 2000, Pages 77-80

  Sugaya, Norio ^a  

^a NIPPON KOKAN HOSPITAL   (Japan)

Author keywords

Amantadine; Influenza vaccine; Neuraminidase inhibitor; Rapid diagnosis; Zanamivir

Indexed keywords

ACICLOVIR; AMANTADINE; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; DEXAMETHASONE; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; TETANUS TOXOID; UNCLASSIFIED DRUG; ZANAMIVIR;

ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; CLINICAL TRIAL; DEVICE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; JAPAN; NAUSEA; REVIEW; VIRUS DIAGNOSIS; VIRUS ENCEPHALITIS;

EID: 0033925764     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012155     Document Type: Review

References (23)

1. Hirota Y, Fedson DS, Kaji M. Japan laaging in influenza jabs. Nature 1996;380:18.
2. Calfee DP, Hayden FG. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs 1998;56:537-53.
3. Mitamura K, Sugaya N, Nirasawa M, Takahashi K, Shimizu H, Hirai Y. Impact of influenza A virus infection as a cause of pediatric hospitalization and use of rapid antigen test of influenza A virus (in Japanese). Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 1998;72:883-9.
4. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1999;48:RR4.
5. Sugiura A, Yanagawa H, Enomoto C, Ueda M, Tobita K. A field trial for evaluation of the prophylactic effect of influenza vaccine containing inactivated A2/Hong Kong and B influenza viruses. J Infect Dis 1970;122:472-8.
6. Hirota Y, Takeshita S, Ide S, Kataoka K, Ohkubo A, Fukuyoshi S, et al. Various factors associated with the manifestation of influenza-like illness. Int J Epidemiol 1992;21:574-82.
7. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994;272:1122-6.
8. Yamakoshi M, Suzuki K, Yamamoto T, Nakakita T, Goto N, et al. Antibody response of inactivated influenza vaccine in the elderly (in Japanese). Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 1998;72:358-64.
9. Ikematsu H, Nabeshima A, Kakuda K, Yamaji K, Hayashi J, Goto S, et al. Impact of influenza epidemics and efficacy of vaccination among geriatric inpatients (in Japanese). Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 1998;72:60-6.
10. Murayama N, Suzuki H, Arakawa M, Nerome K, Mizuta K, Kameyama K. Two outbreaks of influenza A (H3N2) in a Japanese nursing home in the winter of 1996-1997, with differing vaccine efficacy. Tohoku J Exp Med 1999;188:289-98.
11. Horie S, Sugaya N, Mitamura K, Nirasawa M, Takahashi K, Fukazawa T. Immunization with one dose of inactivated influenza vaccine (in Japanese). Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 1998;72:482-6.
12. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infection. Infect Dis Clin North Am 1987;1:459-78.
13. Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza - double-blind studies. Jpn J Tuberc Chest Dis 1971;17:1-7.
14. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35: 1741-7.
15. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992;176:119-30.
16. Togashi T, Matsuzono Y, Anakura M, Nerome K. Acute encephalitis and encephalopathy at the height of influenza in childhood (in Japanese). Nippon Rinsho (Jpn J Clin Med) 1997;55:2699-705.
17. Sugaya N, Miura M. Amantadine therapy for influenza type A-associated encephalopathy. Pediatr Infect Dis J 1999;18:734.
18. Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Katoh T, et al. PCR of cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998;352:873-5.
19. Ito Y, Ichiyama T, Kimura H, Shibata M, Ishiwada N, Kuroki H, et al. Detection of influenza virus RNA by reverse transcription-PCR and proinflammatory cytokines in influenza-virus-associated encephalopathy. J Med Virol 1999;58:420-5.
20. Shinjoh M, Bamba M, Jozaki K, Takahashi E, Koinuma G, Sugaya N. Influenza type A-associated encephalopathy with bilateral thaIamic necrosis in Japan. Clin Infect Dis 2000.
21. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874-80.
22. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor Oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43.
23. Yamazaki M, Kimura K, Watanabe S, Komiyama O, Mishiku Y, Yamamoto K, et al. Use of a rapid detection assay for influenza virus, on nasal aspirate specimens (in Japanese). Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 1999;73:1064-8.